Cadila
Pharmaceuticals Limited believes and works towards providing affordable
healthcare to all. In order to achieve the same, it has always taken steps to
remain ahead of time and keep innovating products that are beyond its generic
nature. In order to offer different pharmaceutical products addressing
different problems, Cadila Pharmaceuticals has addressed many key areas in
modern medicine.
The mission and
goal of Cadila Pharmaceuticals is to produce and provide affordable medicines
to the common people that was first established by the company’s founder
Chairman Shri I A Modi. The basic aim is to offer innovative as well as the
world’s first molecule at an affordable price. Drugs such as Risorine, Polycap
or Mycidac C are such examples that describes the organisation’s commitment to
the cause of offering affordable and cost-effective drugs and medicines to
people.
A major
breakthrough in 2009 took place as with the launch of Polycap, a drug that
helps in preventing cardiovascular diseases. This is a novel drug that has a
combination of three antihypertensive drugs along with aspirin and a statin
(cholesterol lowering drug). The R&D team, in the very same year, also made
a major discovery in the field of tuberculosis as they produced and launched
Risorine. This is the first boosted rifampicin that contains a fixed dose
combination to be used as an anti-tuberculosis drug.
In 2013, Cadila
Pharmaceuticals achieved another milestone with the launch of Mycidac C that is
used for treatment of lung cancer. This is also the first active immunotherapy
drug in the world used for treatment of lung cancer.
For Cadila
Pharmaceuticals, R&D has always been a focus area and an investment of six
to seven percent from the total revenue is done on the same. The
state-of-the-art in house R&D facility has over 350 scientists who works
towards producing many such drugs and medicines that are known to be the
world’s firsts and can be made available for the people at an affordable price.
Cadila Pharmaceuticals
is also known to invest in development of innovative products such as vaccines,
pain management drugs and antibiotics and many other drugs. In their joint
venture with Novavax, the focus has been on development of new vaccine
candidates using virus like particle (VLP) technology. The organisation has
also tied up with NovaSAID based out of Sweden in order to develop innovative
treatment medicines to address inflammation related problems as well as to
manage pain. Cadila Pharmaceuticals’ strategic collaboration with Pergamum AB
is aimed at development of a novel treatment for infections with a unique
targeting mechanism that is clearly distinguished from the other groups of
antibiotics.
No comments:
Post a Comment